Quinuclidine therapeutic agents
CA 2003441 C · Owner: Lowe, John A. Iii · Inventors: Lowe, John A. Iii
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A series of cis-3-(cyclic)methylamino-2- (.alpha.-substituted)arylmethylquinuclidines 3-(cyclic)methylimino-2-(.alpha.-substitituted)arylmethylquinuclidines and cis-3-(cyclic)methyleneamino-2-(.alpha.-substituted)arylmethylquinuclidines, including their pharmaceutically acceptable salts, are disclosed. These particular compounds are found to be useful as substance P antagonists and therefore, are of value in treating gastrointestinal disorders, central nervous system disorders, inflammatory diseases and pain or migraine. Preferred member compounds include cis-3-(2chlorophenyl)methylamino-2-benzhydryl-quinuclidinne cis-3-(2-trifluorophenyl)methylamino2-benzhydrylquinuclidine and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 21, 1989 and granted April 7, 1998. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 21, 2009.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 21, 2011.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.